Pricing Log in Create free account

Arcturus Therapeutics Holdings Inc. (ARCT) vs ARS Pharmaceuticals, Inc. (SPRY)

Arcturus Therapeutics Holdings Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. Arcturus Therapeutics Holdings Inc. and ARS Pharmaceuticals, Inc. are of similar size ($266.0M and $263.5M). ARS Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −14.5% against −68.7%. ARS Pharmaceuticals, Inc. has the higher net margin (0.00% vs −285.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, ARS Pharmaceuticals, Inc. leads on 9 and Arcturus Therapeutics Holdings Inc. on 5.

Valuation

Metric ARCT SPRY Biotechnology median
P/E n/m n/m 10.60
P/S 9.60 2.29 9.40
P/B 1.74 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 6.02 2.57 9.02
Earnings yield (29.90%) (71.89%) (32.88%)
Free cash flow yield (21.30%) (70.96%) (23.13%)

Profitability

Metric ARCT SPRY Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (311.22%) (161.50%) 0.00%
Net margin (285.91%) 0.00% 0.00%
Free cash flow margin (204.48%) (149.89%) 0.00%
Return on equity (44.37%) 0.00% (51.96%)
Return on assets (35.06%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARCT SPRY Biotechnology median
Revenue growth (TTM) (68.74%) (14.45%) 6.76%
EPS growth (last fiscal year) 20.00% (2,275.00%) 29.88%
Revenue growth, 5-year CAGR 53.78% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARCT SPRY Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.68 3.25 4.97
Net debt to EBITDA 3.15 0.42 1.01

Dividend

Metric ARCT SPRY Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ARCT SPRY Biotechnology median
Market cap 266.04m 263.53m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack